Enventric's Neurovascular Device 'EVOGLIDE' Approved by Ministry of Food and Drug Safety

"Precisely Reflecting the Characteristics of Korean Blood Vessels and Clinical Demands"

Enventric, a company specializing in vascular medical devices, announced on January 13 that it has obtained product approval from the Ministry of Food and Drug Safety for its distal access catheter (DAC) 'EVOGLIDE' for neurovascular intervention procedures.

EVOGLIDE is a medical device that serves as a pathway to ensure therapeutic devices can safely reach lesions during the treatment of cerebral aneurysms and cerebral infarctions. Due to the thin and complex structure of cerebral blood vessels, the flexibility, support, and trackability of the catheter are crucial to the success of the procedure. Currently, the domestic and international DAC markets are dominated by imported products such as MicroVention’s 'SOFIA.' In developing this product, Enventric precisely reflected the characteristics of Korean blood vessels and the needs of clinical settings.

In particular, Enventric’s proprietary technology platform 'H-Flex 8' utilizes a hybrid method that combines a shape-memory alloy coil and braiding, along with a variable structure design that divides the catheter into eight segments, achieving both flexibility and pushability. This minimizes kinking of the catheter during procedures while maintaining a wide inner diameter, thereby improving procedural efficiency.

In addition to DACs, Enventric plans to provide a total solution for neurovascular intervention by offering stent retrievers and balloon guide catheters as a package. By producing core processes in-house, the company has also secured price competitiveness compared to global products.

Enventric has attracted investment from Premier Partners, Quad Asset Management, Korea Development Bank, UTC Investment, Kiwoom Securities, Bluepoint Partners, Heungkuk Securities, Devsisters, Hanwha Investment & Securities, and IPS Ventures.

In 2024, sales grew approximately 2.5 times compared to the previous year, and the company is accelerating its entry into global markets such as the United States, Europe, Southeast Asia, and the Middle East. Enventric plans to further accelerate its global expansion and preparations for an initial public offering, using the commercialization of this core product as a springboard.

Min Jiyoung and Min Sungwoo, Co-CEOs of Enventric, stated, "We have demonstrated the technological excellence of domestic products in a neurovascular medical device market previously led by global companies," and added, "We aim to become a global leader in neurovascular solutions."